Navigation Links
Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
Date:5/17/2012

angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements  

Except for statements of historical fact, the matters discussed in this press release or the referenced investor presentation are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third partie
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
2. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
3. Smith Medical Partners Announces Logistics Agreement for Cardiums National Distribution of Excellagen™
4. Cardium Announces Closing of $5.0 Million Equity Financing
5. Cardium Regains Listing Compliance With NYSE Amex
6. Cardium Announces First International Marketing and Distribution Agreement for Commercialization of Excellagen™ in South Korea
7. Cardium Reports on Renewed Compliance With NYSE Amex Exchange Listing Guidelines
8. Cardium and SourceOne Global Partners Enter Into Cross-Strategic Equity Investment with Plans to Jointly Develop Nutritional Supplements and Medical Foods
9. Cardium to Present at the Rodman & Renshaw Annual Healthcare Investment Conference
10. Cardium Provides Update on Exchange Listing and Related Business Matters
11. Cardium to Present at Southern California Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014  Decision Resources Group finds that ... States will increase to a value of ... driven by expansion in the large direct energy device ... be increasingly adopted due to the advantages they offer ... key findings from Decision Resources Group,s coverage of the ...
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
(Date:12/19/2014)... and LYON, France , Dec. 19, ... LLY ) and Adocia (Euronext Paris: FR0011184241 – ADOC) ... an ultra-rapid insulin, known as BioChaperone Lispro, for treatment ... BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® technology and ... and Adocia will develop BioChaperone Lispro with the goal ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
(Date:12/20/2014)... Today, Balfleet.com, one of the most outstanding dressmakers ... off on its Mother of the Bride Dresses ... the bride dresses from Balfleet.com feature gorgeous looks and ... takes pride in providing high quality dresses to its ... discounts on our mother of the bride dresses, and ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 Sweetdressy.com ... market, has introduced its newest selection of cheap prom ... are very popular in the world and clients can ... , Meanwhile, these prom dresses feature cool cuts and ... $200 now, targeting the middle-end market. Discount shipping costs ...
(Date:12/19/2014)... CA (PRWEB) December 19, 2014 ... corporation dedicated to developing educational events, tools and ... Rouxbe Cooking School , the world’s leading ... the prescription every human being needs: Culinary Rx. ... plant-based cooking course, Culinary Rx, scheduled for debut ...
(Date:12/19/2014)... Eufaula, Oklahoma, located just 9 miles ... state’s largest lake with more than 600 miles of ... a little more than 3,000 residents, hosted its annual ... 6th of December. , Featuring Santa, Christmas lights and ... on Main Street. Narconon Arrowhead’s parade float participated ...
(Date:12/19/2014)... (PRWEB) December 20, 2014 The Medspa ... new injectable filler from respected cosmetic brand Juvéderm. Voluma ... naturally with age. The Medspa at Hendrick is pleased ... in skin care technology to its clients. , Voluma ... to be FDA-approved to treat the mid-face and cheek ...
Breaking Medicine News(10 mins):Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... ... a common technology infrastructure for Policy, Compliance, Risk, SOX, Internal Audits and IT ... ... -- MetricStream, Inc. (“MetricStream”), the market leader in the enterprise-wide Governance, Risk ...
... (NYSE Alternext: ULU), a specialty pharmaceutical company ... and oral care products, today announced it has entered into ... at a price per share of $0.14 pursuant to a ... of approximately $1.5 million. , Investors will also receive warrants ...
... Mass., Nov. 12 Cequent Pharmaceuticals, a pioneer in ... to prevent and treat human disease, has announced that ... application with the U.S. Food and Drug Administration (FDA). ... candidate, targets beta-catenin, a key oncogene implicated in the ...
... Nov. 12 Mary Elizabeth Derig, of Seattle, Washington, ... Edition for her outstanding contributions and achievements in the ... ) , ABOUT MARY ELIZABETH ... an extensive career as a Registered Nurse including work ...
... (NYSE: ABT ) announced today a definitive agreement to ... antibody to Nerve Growth Factor (NGF), expanding the company,s pain ... a novel biologic in Phase I clinical trial development that ... released at sites of tissue damage and inflammation, and plays ...
... ... Mary Alexander will present during Class Action/Mass Torts session discussing tainted food products , ... San Francisco, CA (PRWEB) November 12, ... product law firms in the nation, will take the podium during the 48th Annual Consumer ...
Cached Medicine News:Health News:Amedisys Selects MetricStream for Integrated Enterprise-wide GRC 2Health News:ULURU Inc. to Raise $1.5 Million in Registered Direct Offering 2Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 2Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 3Health News:Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology 4Health News:Mary Elizabeth Derig Recognized by Strathmore's Who's Who Worldwide Publication 2Health News:Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain 2Health News:California Consumer Attorney Mary Alexander to Present at 48th Annual COAC Convention 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: